Stock Market News
IXICO wins new contract worth $2.7m with global pharma customer
AIM-listed IXICO, a digital technologies company serving neuroscience, has signed an additional new contract with an existing global pharmaceutical customer worth $2.7m over a seven-year term.
As part of the contract, which begins immediately, IXICO will provide its technology enabled imaging services in a clinical trial of a novel therapeutic to treat people with progressive supranuclear palsy (PSP), a rare neurodegenerative disease which leads to difficulties with balance, movement, vision, speech and swallowing.
This new contract is IXICO's third clinical trial project in PSP and follows contracts announced in October 2016 and March 2017 with values of $1.2m and $1.5m, respectively.
As part of the study, IXICO will use its TrialTracker digital platform and image analysis algorithms to collect and analyse MRI data from specialist imaging centres across Europe, North America and Australasia. The data will then be used to evaluate the safety and efficacy of the treatment.
Chief executive officer Giulio Cerroni said: "This additional, new contract in PSP from an existing customer indicates the value our customers see in IXICO's extensive neurological disease expertise combined with our proprietary digital technologies. Through our proven ability to collect and analyse clinical data in a standardized and regulatory-complaint format, we continue to build on our successful track record as a partner of choice to the biopharmaceutical industry."
At 1010 GMT, the shares were up 8.4% to 36.85p.
As part of the contract, which begins immediately, IXICO will provide its technology enabled imaging services in a clinical trial of a novel therapeutic to treat people with progressive supranuclear palsy (PSP), a rare neurodegenerative disease which leads to difficulties with balance, movement, vision, speech and swallowing.
This new contract is IXICO's third clinical trial project in PSP and follows contracts announced in October 2016 and March 2017 with values of $1.2m and $1.5m, respectively.
As part of the study, IXICO will use its TrialTracker digital platform and image analysis algorithms to collect and analyse MRI data from specialist imaging centres across Europe, North America and Australasia. The data will then be used to evaluate the safety and efficacy of the treatment.
Chief executive officer Giulio Cerroni said: "This additional, new contract in PSP from an existing customer indicates the value our customers see in IXICO's extensive neurological disease expertise combined with our proprietary digital technologies. Through our proven ability to collect and analyse clinical data in a standardized and regulatory-complaint format, we continue to build on our successful track record as a partner of choice to the biopharmaceutical industry."
At 1010 GMT, the shares were up 8.4% to 36.85p.
Related share prices |
---|
Ixico (IXI) share price |
Stock News headlines are gathered from financial news sources around the web. Views and opinions on each item are from their respective authors and website. They are not opinions of LiveCharts.co.uk
Get a free widget for your website with our latest headlines.
You can now add our live prices and new headlines to your website.The news widget features quotes for Oil prices, spot Gold price and Indices plus a choice of news channel for healines.
Top Shares pages
- Share price quotes
- Share charts
- Share watch list
- Company Results Calendar
- Top Large UK Shares
- UK Market Sectors
- Stock market news
- Company news
- Share tips
- A-Z company search
More share features
POPULAR Share Prices
- Royal Mail share price
- Lloyds share price
- HSBC share price
- Barclays share price
- Prudential share price
- Santander share price
- NEXT share price
- Diageo share price
- BP share price
- Vodafone share price
- British Airways
- Centrica share price
- Tesco share price
- Taylor Wimpey Share Price
- National Grid
- GKP Share Price
- Marks and Spencer
- Rolls Royce
- Rio Tinto
- THG Share Price
- Aviva Share Price
- Boil Share price
- Easyjet Share Price
- Genedrive Share Price
- SSE Share Price
- IAG Share Price
- Boohoo share price
- HE1 share price
- AVCT share price
- BOOM share price